Sign in

    ZimVie Inc (ZIMV)

    Q2 2024 Earnings Summary

    Reported on Apr 3, 2025 (After Market Close)
    Pre-Earnings Price$20.40Last close (Aug 1, 2024)
    Post-Earnings Price$18.80Open (Aug 2, 2024)
    Price Change
    $-1.60(-7.84%)

    What went well

    • ZimVie's digital solutions, including guided software and Implant Concierge services, are each growing over 20%, indicating strong demand and potential for revenue expansion. This growth reflects a movement towards guided surgery and outsourcing of lab work, suggesting stabilizing market demand.
    • The company is focusing on the premium dental implant market, maintaining excellent gross profit margins and strong pricing power, even as competitors exit the segment. Their rapidly growing and highly differentiated digital offerings, such as Implant Concierge and GenTek, uniquely position them to expand the market.
    • ZimVie is experiencing growth in the Asia Pacific region (excluding China), with constant currency growth of 1.1% in Q2 2024, particularly in fast-growing markets like India and Australia. This strategic positioning in high-growth markets supports potential future revenue growth.

    What went wrong

    • ZimVie expects Q3 2024 revenue to be sequentially lower versus Q2 and lower year-over-year by 3% to 4%, indicating continued market challenges.
    • The company has experienced pressure on capital sales, specifically in oral scanners, with lower equipment sales impacting revenue, and the delay in Lumina's restorative launch has affected 2024 projections.
    • Executives acknowledge that the underlying market challenges have not completely subsided, and the market is not well on the road to recovery, leading to a prudent outlook for Q3 2024.

    Q&A Summary

    1. Margin Outlook and 2025 Expectations
      Q: What's the EBITDA margin outlook into 2025?
      A: Management expects an approximately 12% adjusted EBITDA margin in Q3 2024 due to seasonal revenue decline affecting fixed costs. They anticipate margins to improve in Q4, potentially reaching closer to 16%, positioning the company well for achieving 15%+ adjusted EBITDA margins by April 1, 2025.

    2. Market Outlook and Patient Demand
      Q: Is market decline due to factors beyond seasonality?
      A: Despite strong Q2 performance driven by portfolio differentiation and execution , management notes that the broader dental market hasn't fully recovered. They are cautious about Q3, expecting a 3% to 4% year-over-year revenue decline , as underlying market challenges persist.

    3. Strategic Positioning and Potential M&A
      Q: Will you remain open or consider strategic interest?
      A: CEO Vafa Jamali emphasizes running the company with a long-term focus, highlighting their unique assets and strong position in the premium dental implant market. They plan to maintain an open software platform for strategic advantage unless significant market share dictates otherwise.

    4. iTero Lumina Delay and Medit Partnership
      Q: Did Lumina's delay impact 2024 outlook? How does Medit partnership help?
      A: The delay of Lumina's restorative launch was anticipated and included in the full-year guidance. Lower equipment sales impacted digital offerings, but the new partnership with Medit provides a rich offering without sacrificing technology. This helps advance customers to a digital platform, accelerating implant usage and improving implant quality.

    5. Growth Strategy in Dental Implants
      Q: How will you achieve desired scale in dental?
      A: The company focuses on its unique assets in the premium dental implant market, maintaining excellent gross profit margins and holding price. They're expanding digital offerings like Implant Concierge and GenTek to grow the market and considering selective entry into new segments.

    6. Asia Pacific Growth and China Exposure
      Q: What's happening with Asia Pacific growth and China exposure?
      A: ZimVie's exposure to China is minimal, limiting impact from market volatility there. In Asia Pacific, they achieved 1.1% growth in constant currency despite a 6.9% reported decline due to currency fluctuations. Strong performance in Japan, India, and Australia is driving growth.

    7. Market Trends from Software Insights
      Q: What are your software insights on market trends?
      A: The company sees over 20% growth in both Implant Concierge and surgical guide sales with RealGUIDE software, indicating a movement toward guided surgery and outsourced lab work. Increased biomaterials sales suggest market stabilization and potential future implant demand.

    Related Publications